Pre-Market Analysis: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc.

LONDON, August 20, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

The US equity market closed on a lower note on Monday, August 19, 2013. All three benchmark indexes declined, with the Dow Jones Industrial Average falling 0.47%, the S&P 500 falling 0.59%, and the NASDAQ composite declining 0.38%. Shares in the healthcare industry ended on a mixed note, even as the broader market declined. The major movers in the sector included Dendreon Corporation (NASDAQ: DNDN), Stryker Corporation (NYSE: SYK), Novartis AG (NYSE: NVS), and Repros Therapeutics Inc. (NASDAQ: RPRX). All these companies are tracked by AAAResearchReports.com. Free technical research on DNDN, SYK, NVS, and RPRX can be downloaded upon signing up at:

http://www.aaaresearchreports.com/register/  

Shares in Dendreon Corporation ended the day 0.94% lower at $3.15 after fluctuating between $3.13 and $3.28. A total of 3.58 million shares were traded, which is below the daily average volume of 4.09 million. The company's shares have lost 0.94% in the last three trading sessions, outperforming the S&P 500 which has lost 2.33% during the same period. Moreover, the stock is currently trading below its 50-day and 200-day moving averages. Sign up and read the complimentary report on DNDN at:

http://www.AAAResearchReports.com/DNDN082013.pdf

Stryker Corporation's stock ended slightly higher on Monday, finishing at $68.06, up 0.13% from its previous closing price. The company's shares fluctuated between $67.82 and $68.54. A total of 0.83 million shares were traded, which is below the daily average volume of 1.27 million. The company's shares have lost 1.22% in last three months, outperforming the S&P 500 which has lost 1.28% during the same period. The free report on SYK can be downloaded by signing up now at:

http://www.AAAResearchReports.com/SYK082013.pdf

Shares in Novartis AG posted modest gains on Monday. The company's shares traded between $72.81 and $73.21 before finishing the day 0.08% higher at $72.90. A total of 1.53 million shares were traded, which is above the daily average volume of 1.43 million. The company's shares have gained 0.45% in the last one month, compared to a loss of 2.72% in the S&P 500 during the same period. Furthermore, the stock is currently trading above its 50-day and 200-day moving averages. A free report on NVS can be accessed by registering at:

http://www.AAAResearchReports.com/NVS082013.pdf

Shares in Repros Therapeutics Inc. fell sharply on Monday as the broader market finished on a lower note. The company's shares ended the session 2.16% lower at $19.01 after oscillating between $18.90 and $19.97. A total of 0.52 million shares were traded, which is above the daily average volume of 0.43 million. The company's shares have gained 1.93% in the last three trading sessions, and 13.90% in the last three months, outperforming the S&P 500 which has lost 2.33% and 1.28%, during the respective periods. Moreover, the stock is currently trading above its 200-day moving average. Register with AAA Research Reports and download research on RPRX for free at:

http://www.AAAResearchReports.com/RPRX082013.pdf

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.AAAresearchreports.com

SOURCE AAA Research Reports